椎体成形术与保守治疗急性骨质疏松性椎体压缩骨折(Vertos II):一项开放标签随机试验。

Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial.

机构信息

Radiology, St Elisabeth Ziekenhuis, Tilburg, Netherlands.

出版信息

Lancet. 2010 Sep 25;376(9746):1085-92. doi: 10.1016/S0140-6736(10)60954-3. Epub 2010 Aug 9.

Abstract

BACKGROUND

Percutaneous vertebroplasty is increasingly used for treatment of pain in patients with osteoporotic vertebral compression fractures, but the efficacy, cost-effectiveness, and safety of the procedure remain uncertain. We aimed to clarify whether vertebroplasty has additional value compared with optimum pain treatment in patients with acute vertebral fractures.

METHODS

Patients were recruited to this open-label prospective randomised trial from the radiology departments of six hospitals in the Netherlands and Belgium. Patients were aged 50 years or older, had vertebral compression fractures on spine radiograph (minimum 15% height loss; level of fracture at Th5 or lower; bone oedema on MRI), with back pain for 6 weeks or less, and a visual analogue scale (VAS) score of 5 or more. Patients were randomly allocated to percutaneous vertebroplasty or conservative treatment by computer-generated randomisation codes with a block size of six. Masking was not possible for participants, physicians, and outcome assessors. The primary outcome was pain relief at 1 month and 1 year as measured by VAS score. Analysis was by intention to treat. This study is registered at ClinicalTrials.gov, number NCT00232466.

FINDINGS

Between Oct 1, 2005, and June 30, 2008, we identified 431 patients who were eligible for randomisation. 229 (53%) patients had spontaneous pain relief during assessment, and 202 patients with persistent pain were randomly allocated to treatment (101 vertebroplasty, 101 conservative treatment). Vertebroplasty resulted in greater pain relief than did conservative treatment; difference in mean VAS score between baseline and 1 month was -5·2 (95% CI -5·88 to -4·72) after vertebroplasty and -2·7 (-3·22 to -1·98) after conservative treatment, and between baseline and 1 year was -5·7 (-6·22 to -4·98) after vertebroplasty and -3·7 (-4·35 to -3·05) after conservative treatment. The difference between groups in reduction of mean VAS score from baseline was 2·6 (95% CI 1·74-3·37, p<0·0001) at 1 month and 2·0 (1·13-2·80, p<0·0001) at 1 year. No serious complications or adverse events were reported.

INTERPRETATION

In a subgroup of patients with acute osteoporotic vertebral compression fractures and persistent pain, percutaneous vertebroplasty is effective and safe. Pain relief after vertebroplasty is immediate, is sustained for at least a year, and is significantly greater than that achieved with conservative treatment, at an acceptable cost.

FUNDING

ZonMw; COOK Medical.

摘要

背景

经皮椎体成形术越来越多地用于治疗骨质疏松性椎体压缩骨折患者的疼痛,但该手术的疗效、成本效益和安全性仍不确定。我们旨在阐明椎体成形术与急性椎体骨折患者的最佳疼痛治疗相比是否具有额外的价值。

方法

本开放性前瞻性随机试验招募了来自荷兰和比利时六家医院放射科的患者。患者年龄在 50 岁或以上,在脊柱 X 线片上有椎体压缩骨折(最小 15%的高度丢失;骨折水平在 Th5 或以下;MRI 上有骨水肿),背痛持续 6 周或更短,视觉模拟量表(VAS)评分在 5 或更高。患者通过计算机生成的随机化代码和大小为六的分组随机分配至经皮椎体成形术或保守治疗。参与者、医生和结果评估者无法进行盲法。主要结局是 VAS 评分测量的 1 个月和 1 年的疼痛缓解情况。分析采用意向治疗。本研究在 ClinicalTrials.gov 注册,编号为 NCT00232466。

发现

在 2005 年 10 月 1 日至 2008 年 6 月 30 日期间,我们确定了 431 名符合随机分组条件的患者。229 名(53%)患者在评估过程中有自发性疼痛缓解,202 名持续疼痛的患者被随机分配至治疗组(101 名椎体成形术,101 名保守治疗)。与保守治疗相比,椎体成形术的疼痛缓解更明显;椎体成形术后 VAS 评分从基线到 1 个月的平均差值为-5.2(95%CI -5.88 至-4.72),而保守治疗为-2.7(-3.22 至-1.98),椎体成形术后从基线到 1 年的平均差值为-5.7(-6.22 至-4.98),而保守治疗为-3.7(-4.35 至-3.05)。与基线相比,两组的 VAS 评分平均差值在 1 个月时为 2.6(95%CI 1.74-3.37,p<0.0001),在 1 年时为 2.0(1.13-2.80,p<0.0001)。没有报告严重并发症或不良事件。

解释

在急性骨质疏松性椎体压缩骨折和持续疼痛的亚组患者中,经皮椎体成形术是有效且安全的。椎体成形术后疼痛缓解是即时的,至少持续 1 年,且明显大于保守治疗,成本也可接受。

资金

ZonMw;COOK 医疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索